Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shock waves could soften hand contractures without surgery

NCT ID NCT06248866

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests whether extracorporeal shock wave therapy can reduce the thickness of fibrous tissue in the hand caused by palmar fibromatosis (Dupuytren's contracture). Adults aged 18 to 70 with nodules, cords, or contractures will receive either shock wave therapy plus standard care or standard care alone. Researchers will measure changes in lesion thickness using ultrasound and assess hand function with a questionnaire.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
extracorporeal shock wave therapy
What this could lead to
If it works, this could offer a non-surgical option to reduce nodules and cords in the hand and improve daily function.
What could go wrong
This is a small, early-stage trial with 60 participants, so results may not apply broadly. The therapy may not shrink lesions or improve symptoms significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Mar 2024

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with palmar fibromatosis. * Adults aged 18 to 70 years. * Patients of any stage of physiological change of the disease (nodules cords and contractures). Exclusion Criteria: * Patients with contraindications to extracorporeal shock wave therapy. * Patients with a history of previous surgery for palmar fibromatosis. * Patients with comorbidities or conditions that may affect the outcomes of the study. * Patients of ganglions and palmar tendon fibrosis. * Patients of sever and morbid obesity. * End stage disease with psychological disturbance nature. * Pregnant women. * Cardiac and pulmonary unstable patients may affect results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Palmar fibromatosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

palmar fibromatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Palmar fibromatosis

Contacts and locations

Locations

  • Outpatient clinic, ministry of health at sohag hospitals

    Sohag, 82511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.